➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Express Scripts
Medtronic
Moodys
Boehringer Ingelheim

Last Updated: June 12, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-653


Email this page to a colleague

« Back to Dashboard

What is the drug development status for TAK-653?

TAK-653 is an investigational drug.

There have been 348 clinical trials for TAK-653. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are seven US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for TAK-653
TitleSponsorPhase
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)Janssen Pharmaceutical K.K.Phase 3
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersTakedaPhase 1
A Study of TAK-994 in Adults With NarcolepsyTakedaPhase 2

See all TAK-653 clinical trials

Clinical Trial Summary for TAK-653

Top disease conditions for TAK-653
Top clinical trial sponsors for TAK-653

See all TAK-653 clinical trials

US Patents for TAK-653

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-653   Get Started Free Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Get Started Free
TAK-653   Get Started Free Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Get Started Free
TAK-653   Get Started Free Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Get Started Free
TAK-653   Get Started Free Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Get Started Free
TAK-653   Get Started Free Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Get Started Free
TAK-653   Get Started Free Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Get Started Free
TAK-653   Get Started Free   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-653

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-653 Argentina AR082618 2030-08-10   Get Started Free
TAK-653 Australia AU2011290126 2030-08-10   Get Started Free
TAK-653 Brazil BR112013002250 2030-08-10   Get Started Free
TAK-653 Canada CA2807460 2030-08-10   Get Started Free
TAK-653 Chile CL2013000380 2030-08-10   Get Started Free
TAK-653 China CN103180326 2030-08-10   Get Started Free
TAK-653 China CN104926837 2030-08-10   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Baxter
Medtronic
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.